HURA logo

TUHURA BIOSCIENCES INC

HURANASDAQ
πŸ† #3949 by market capEarnings Mar 29 Β· PostUS Equity
$1.25β–Ό $0.11 (βˆ’8.42%)
Market closed Β· at close
πŸ””
Track HURA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 8.4%
7dβ–Ό 10.1%
14dβ–Ό 23.3%
30dβ–Ό 42.7%
ytdβ–² 67.0%
1yβ–Ό 27.7%
🏦Market Cap
$82M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.25 – $1.34
52-Week Range
$0.41 – $3.43
Volume (shares)
12,668
Avg Volume (shares)
β€”
Shares Outstanding
65.8M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-2.5
P/S Ratio
0.0x
EPS (TTM)
$-0.46
Dividend Yield
0.00%
Dilution (1yr)
+13.2%
HURA logo

TUHURA BIOSCIENCES INC

HURA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$32Mβ–² +80.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$28Mβ–² +87.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.9Mβ–² +13.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3Mβ–Ό βˆ’$10M YoY
StockOtter Β· stockotter.space

About TUHURA BIOSCIENCES INC

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.